OGN – Organon & Co.
OGN — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
7.46
Margin Of Safety %
1
Put/Call OI Ratio
0.87
EPS Next Q Diff
0.22
EPS Last/This Y
2.72
EPS This/Next Y
0.22
Price
13.35
Target Price
11.25
Analyst Recom
3.5
Performance Q
73.47
Upside
-8.4%
Beta
1.54
Ticker: OGN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-14 | OGN | 8.7 | 0.55 | 0.25 | 128567 |
| 2026-04-15 | OGN | 9.23 | 0.54 | 0.19 | 131434 |
| 2026-04-16 | OGN | 9.34 | 0.52 | 0.34 | 136374 |
| 2026-04-17 | OGN | 9.76 | 0.52 | 0.18 | 146704 |
| 2026-04-20 | OGN | 9.25 | 0.55 | 0.94 | 133162 |
| 2026-04-21 | OGN | 8.85 | 0.56 | 1.19 | 138870 |
| 2026-04-22 | OGN | 9.15 | 0.60 | 0.03 | 144712 |
| 2026-04-23 | OGN | 8.6 | 0.49 | 0.07 | 165995 |
| 2026-04-24 | OGN | 11.26 | 0.45 | 0.27 | 177355 |
| 2026-04-27 | OGN | 13.17 | 0.43 | 0.36 | 219000 |
| 2026-04-28 | OGN | 13.32 | 0.53 | 0.20 | 226093 |
| 2026-04-29 | OGN | 13.34 | 0.67 | 0.09 | 214216 |
| 2026-04-30 | OGN | 13.25 | 0.64 | 1.26 | 221138 |
| 2026-05-01 | OGN | 13.3 | 0.65 | 0.24 | 222071 |
| 2026-05-04 | OGN | 13.27 | 0.66 | 0.09 | 221700 |
| 2026-05-05 | OGN | 13.35 | 0.66 | 0.23 | 221460 |
| 2026-05-06 | OGN | 13.39 | 0.66 | 2.34 | 220880 |
| 2026-05-07 | OGN | 13.31 | 0.67 | 0.43 | 221873 |
| 2026-05-08 | OGN | 13.35 | 0.68 | 4.71 | 222802 |
| 2026-05-11 | OGN | 13.32 | 0.89 | 0.16 | 194765 |
| 2026-05-12 | OGN | 13.3 | 0.88 | 0.10 | 195877 |
| 2026-05-13 | OGN | 13.33 | 0.87 | 0.66 | 196741 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-14 | OGN | 8.70 | -14.9 | - | 3.47 |
| 2026-04-15 | OGN | 9.24 | -14.9 | - | 3.47 |
| 2026-04-16 | OGN | 9.34 | -14.9 | - | 3.47 |
| 2026-04-17 | OGN | 9.76 | -14.9 | - | 3.47 |
| 2026-04-20 | OGN | 9.25 | -14.9 | - | 3.47 |
| 2026-04-21 | OGN | 8.85 | -14.9 | - | 3.47 |
| 2026-04-22 | OGN | 9.14 | -14.9 | - | 3.47 |
| 2026-04-23 | OGN | 8.60 | -14.5 | - | 3.47 |
| 2026-04-24 | OGN | 11.28 | -16.3 | - | 3.47 |
| 2026-04-27 | OGN | 13.16 | -16.3 | - | 3.45 |
| 2026-04-28 | OGN | 13.33 | -16.3 | - | 3.45 |
| 2026-04-30 | OGN | 13.25 | -16.3 | - | 3.45 |
| 2026-05-01 | OGN | 13.30 | -16.3 | - | 3.45 |
| 2026-05-04 | OGN | 13.27 | -16.3 | - | 3.45 |
| 2026-05-05 | OGN | 13.34 | -7.9 | - | 3.44 |
| 2026-05-06 | OGN | 13.40 | -7.9 | - | 3.44 |
| 2026-05-07 | OGN | 13.31 | -7.9 | - | 3.44 |
| 2026-05-08 | OGN | 13.35 | -7.9 | - | 3.44 |
| 2026-05-11 | OGN | 13.32 | -7.9 | - | 3.44 |
| 2026-05-12 | OGN | 13.30 | -7.9 | - | 3.44 |
| 2026-05-13 | OGN | 13.35 | -7.9 | - | 3.44 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-14 | OGN | 5.78 | -1.41 | 8.54 |
| 2026-04-15 | OGN | 5.78 | -1.41 | 8.54 |
| 2026-04-16 | OGN | 5.78 | -1.41 | 8.54 |
| 2026-04-17 | OGN | 5.78 | -1.41 | 8.54 |
| 2026-04-20 | OGN | 5.78 | -1.31 | 8.54 |
| 2026-04-21 | OGN | 5.78 | -1.31 | 8.54 |
| 2026-04-22 | OGN | 5.78 | -1.31 | 8.54 |
| 2026-04-23 | OGN | 5.78 | -1.31 | 8.55 |
| 2026-04-24 | OGN | 5.18 | -1.31 | 8.55 |
| 2026-04-27 | OGN | 5.18 | -0.77 | 7.19 |
| 2026-04-28 | OGN | 5.18 | -0.77 | 7.19 |
| 2026-04-29 | OGN | 5.18 | -0.77 | 7.19 |
| 2026-04-30 | OGN | 5.18 | -0.77 | 7.19 |
| 2026-05-01 | OGN | 5.13 | -0.77 | 0 |
| 2026-05-04 | OGN | 5.13 | -1.24 | 7.12 |
| 2026-05-05 | OGN | 5.13 | -1.24 | 7.12 |
| 2026-05-06 | OGN | 5.13 | -1.24 | 7.12 |
| 2026-05-07 | OGN | 7.36 | -1.24 | 7.12 |
| 2026-05-08 | OGN | 7.36 | -1.24 | 7.12 |
| 2026-05-11 | OGN | 7.36 | -0.39 | 7.12 |
| 2026-05-12 | OGN | 7.36 | -0.39 | 7.46 |
| 2026-05-13 | OGN | 7.07 | -0.39 | 7.46 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.71
Avg. EPS Est. Current Quarter
0.92
Avg. EPS Est. Next Quarter
0.93
Insider Transactions
7.07
Institutional Transactions
-0.39
Beta
1.54
Average Sales Estimate Current Quarter
1556
Average Sales Estimate Next Quarter
1568
Fair Value
13.45
Quality Score
65
Growth Score
40
Sentiment Score
40
Actual DrawDown %
66.2
Max Drawdown 5-Year %
Target Price
11.25
P/E
14.21
Forward P/E
3.64
PEG
2.21
P/S
0.57
P/B
3.88
P/Free Cash Flow
5.13
EPS
0.94
Average EPS Est. Cur. Y
3.44
EPS Next Y. (Est.)
3.66
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
3.99
Relative Volume
0.59
Return on Equity vs Sector %
0.4
Return on Equity vs Industry %
-9.8
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.03
EBIT Estimation
◆
OGN
Healthcare
$13.34
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
77.4
Range 1M
98%
Sup Dist
0.4%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-6%
EPS NY
6.4%
52W%
98.7%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+125.5% upside
Upside
+125.5%
Quality
65
MoS
1%
Organon & Co.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 10000
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
OGN
Latest News
—
Caricamento notizie per OGN…
stock quote shares OGN – Organon & Co. Stock Price stock today
news today OGN – Organon & Co. stock forecast ,stock prediction 2023 2024 2025
marketwatch OGN – Organon & Co. yahoo finance google finance
stock history OGN – Organon & Co. invest stock market
stock prices OGN premarket after hours
ticker OGN fair value insiders trading